Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraxpharm’s New Belgian Division Advances European Expansion Strategy

New Unit Plans To Launch Products From Recent Sanofi Acquisition

Executive Summary

Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established. 

You may also be interested in...



Neuraxpharm Expands Into Brazil And Mexico

In a two-pronged push into Latin America, European CNS specialist Neuraxpharm has set up operations in Mexico and Brazil, with the latter bolstered by the acquisition of local player Libber Pharma.

Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile

Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.

Neuraxpharm Parts Company With API Subsidiary Inke

In light of its ongoing focus on European expansion and a desire to sharpen concentration on its central CNS business, Neuraxpharm has opted to divest its API subsidiary Inke to a private equity firm.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel